Immutep Publishes Presentation on IMP761 Phase I Study

• Immutep published a medical research presentation on its LAG-3 agonist antibody IMP761, including interim Phase 1 results.
• The placebo-controlled study in 60 healthy volunteers showed significant, exposure-dependent suppression of KLH-induced immune responses.
• IMP761 was well tolerated across all tested doses, with no severe or serious adverse events reported.
• Pharmacokinetic findings support dosing every four weeks at higher dose levels of 2.5-14 mg/kg.
• Preclinical testing showed significantly reduced T-cell proliferation and activation in samples from rheumatoid arthritis patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.